ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting

    Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover

    Anne C. Bay-Jensen1, Inger Byrjalsen2, Andrew Kenwright3, Thierry Sornasse4, Claus Christiansen5 and Morten Asser Karsdal6, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Research & Development, Nordic Bioscience, Herlev, Denmark, 3Roche, Welwyn Garden City, United Kingdom, 4Genentech, South San Francisco, 5CCBR, Ballerup, Denmark, 6Nordic Bioscience A/S, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
  • Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting

    Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody® For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile

    Maarten Van Roy1, Hans Ulrichts2, Stefaan Rossenu2, Sandy Jacobs2, Sofie Poelmans3, Gert Verheyden2, Michel Vierboom4, Bert 't Hart4, Judith Baumeister1 and Josefin-Beate Holz5, 1Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 2Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 3Pharmacology, Ablynx NV, Gent, Belgium, 4Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, 5Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
  • Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease

    Hirotoshi Kikuchi1, Maki Takayama2, Yoshitaka Kimura2, Kurumi Asako2, Hajime Kono2, Yasuo Ono1 and Shunsei Hirohata3, 1Department of Microbiology and Immunology, Teikyo University Shool of Medicine, Tokyo, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…
  • Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

    Steven De Bruyn1, Béla Gachályi2, Bernadette Rojkovich3, Slavomir Bruk4, Petr Sramek5, Mariusz Korkosz6, Krzysztof Krause7, Pieter Schoen8, Laura Sargentini-Maier9, Joke D'Artois10, Katrien Verschueren10, Katelijne De Swert10, Gerhard Arold11 and Josefin-Beate Holz12, 1Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, 2Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, 3II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, 4Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, 5Pharmaceutical Research Associates CZ, Praha, Czech Republic, 6Malopolskie Centrum Medyczne, Krakow, Poland, 7Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, 8Project Management, Ablynx N.V., Zwijnaarde, Belgium, 9Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 10Clinical Development, Ablynx nv, Zwijnaarde, Belgium, 11Medical Affairs, PRA International GmbH, Berlin, Germany, 12Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
  • Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting

    STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis

    Jehad H. Edwan1, Tri M. Tran2, Mones Abu-Asab3, Raphaela T. Goldbach-Mansky4 and Robert A. Colbert1, 1NIAMS NIH, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD, 3NEI NIH, Bethesda, MD, 4Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

    Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
  • Abstract Number: 2329 • 2012 ACR/ARHP Annual Meeting

    Increase of CD4+CD25+FoxP3+ T Cell in Patients with Systemic Sclerosis Could Secret IL-17 with Dysfunction of Immunosuppression

    Xinjuan Liu1, Na Gao1, Mengtao Li1, Dong Xu1, Yong Hou1, Qian Wang1, Guohua Zhang1, Qiuning Sun2, Henghui Zhang3 and Xiaofeng Zeng4, 1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 2Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 3Hepatology Institute, Peking University, People's Hospital, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background/Purpose:  Immune unbalance between Th17 and regulatory T cells (Treg) is a characteristic of systemic sclerosis (SSc). The functional heterogeneity and differentiation dynamics can be…
  • Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting

    First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis

    Stanislav Ignatenko1, Birte K. Skrumsager2, Adam Steensberg3 and Ulrik Mouritzen3, 1Charité Research Organization GmbH, Berlin, Germany, 2Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, 3Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark

    Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
  • Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting

    The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)

    Ioannis Kalampokis1, Jeffrey A. Dvergsten2 and Thomas Tedder3, 1Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 2Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, 3Department of Immunology, Duke University Medical Center, Durham, NC

    Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
  • Abstract Number: 2293 • 2012 ACR/ARHP Annual Meeting

    Interleukin-17A Positive Cells Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated to Skin Thickness

    Marie-Elise Truchetet1, Nicolò Costantino Brembilla1, Elisa Montanari1, Paola Lonati2, Pier Luigi Meroni3 and Carlo Chizzolini1, 1University hospital of Geneva, Geneva, Switzerland, 2Division of Rheumatology, Istituto G. Pini, University of Milan, Milan, Italy, 3Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy

    Background/Purpose: T cell producing IL-17A are increased in the peripheral blood of individuals affected by systemic sclerosis (SSc). We asked the question whether IL-17A-producing cells…
  • Abstract Number: 1209 • 2012 ACR/ARHP Annual Meeting

    Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis

    Sabine Blaschke1, Sandra Trautmann1, Alexander W. Beham2, Burkhard Mai3, Sebastian Koelling1, Caroline Breysach4, Gabriele Wolf1, Gerhard A. Mueller1 and Nicolai Miosge5, 1Nephrology & Rheumatology, University Medical Center Goettingen, Goettingen, Germany, 2Department of Surgery, Germany, 3Vitos Orthopaedic Clinic Kassel, Kassel, Germany, 4Department of Surgery, Goettingen, Germany, 5Dept. of Prosthodontics, Goettingen, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of still unknown etiology leading to progressive cartilage and bone destruction. Proinflammatory cytokines, immunoregulatory cells…
  • Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting

    Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)

    Robert R. Evans1, Steven P. Weinstein2, George D. Yancopoulos3 and Yuhwen Soo4, 1Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 2Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology